

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



13 MAY 2005



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/045511 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2003/036123

(22) International Filing Date:
14 November 2003 (14.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/426,664 15 November 2002 (15.11.2002) US
10/658,115 8 September 2003 (08.09.2003) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/426,664 (CIP)
Filed on 15 November 2002 (15.11.2002)
US 10/658,115 (CIP)
Filed on 8 September 2003 (08.09.2003)

(71) Applicants (for all designated States except US): **THE SALK INSTITUTE FOR BIOLOGICAL STUDIES** [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US). **THE SCRIPPS RESEARCH INSTITUTE** [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DOWNES, Michael, R.** [AU/US]; 3440 Lebon Drive, Apt. 4210, San Diego, CA

92122 (US). **EVANS, Ronald, Mark** [US/US]; 1471 Cottontail Lane, La Jolla, CA 92037 (US). **HUGHES, Robert** [GB/US]; 800 N. Lindberg, Q403, Creve Couer, MO 63167 (US). **NICOLAOU, Kyriacos, C.** [US/US]; 9625 Blackgold Road, La Jolla, CA 92037 (US). **ROECKER, Anthony, J.** [US/US]; 3337 Clairemont Drive, #4, San Diego, CA 92117 (US).

(74) Agents: **REITER, Stephen, E.** et al.; Foley & Lardner, P.O. Box 80278, San Diego, CA 92138-0278 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NON-STEROIDAL FARNESOID X RECEPTOR MODULATORS**

(57) **Abstract:** The efficient regulation of cholesterol synthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. In accordance with the present invention, the identification of novel potent FXR activators is described. Two derivatives of invention compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds are useful as chemical tools to further define the physiological role of FXR as well as therapeutic leads for the treatment of diseases linked to cholesterol, bile acids and their metabolism and homeostasis.